Apolipoprotein E/ApoE Antibody (EP1373Y)

Product Discontinued

Apolipoprotein E/ApoE Antibody (EP1373Y) Summary

• Immunogen: A synthetic peptide corresponding to residues near the N-term of human apolipoprotein E was used as an immunogen.
• Localization: Secreted.
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit
• Gene: APOE
• Purity: Protein A purified

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 1:30
  • Immunohistochemistry 1:10-1:500
  • Immunohistochemistry-Paraffin 1:100-1:250
  • Immunoprecipitation 1:70
  • Western Blot 1:1000-10000
• Theoretical MW: 36 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• Control:

  Apolipoprotein E/ApoE Overexpression Lysate

Reactivity Notes

Mouse reactivity reported in scientific literature (PMID: 24259049).

Packaging, Storage & Formulations

• Storage: Store at -20C. Avoid freeze-thaw cycles.
• Buffer: 49% PBS, 0.05% BSA and 50% Glycerol
• Preservative: 0.01% Sodium Azide
• Purity: Protein A purified

Notes

Produced using Abcam's RabMab® technology. RabMab® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

Alternate Names for Apolipoprotein E/ApoE Antibody (EP1373Y)

• APOE
• Apo-E
• Apolipoprotein E
• apolipoprotein E3
• late onset)
• MGC1571

Background

The apolipoproteins are family of amphipathic lipoproteins that plays a crucial role in lipid metabolism. In particular, apolipoprotein E (apo E) is a major component of high density lipoproteins (HDL) chylomicrons and very low-density lipoprotein (VLDL), which functions to remove excess cholesterol. Apo E mediates lipid metabolism and cholesterol homeostasis by binding to several hepatic lipoprotein receptors, such as low density lipoprotein receptor (LDLR) and the LDLR-related protein (1). Apo E deficiency is linked to hyperlipoproteinemia type III; a genetic disorder characterized by elevated plasma cholesterol and triglyceride levels and accelerated coronary artery disease (2). Three major isoforms of Apo E (E2, E3, E4) has been identified, with E3 being the most common in human. E4 presence has been associated to increase probability of developing late-onset form of Alzheimer disease (3).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Apolipoprotein E/ApoE Antibody (NB110-55467)(1)

Publication using NB110-55467

• Hudry E, Dashkoff J, Roe AD et al. Gene transfer of human apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. Sci Transl Med. 2013-11-20 [PMID: 24259049] (Human, Mouse)

FAQs for Apolipoprotein E/ApoE Antibody (NB110-55467). (Showing 1 - 2 of 2 FAQ).

1. What is the concentration of this product?
   • The current lot number is GR198809 with a concentration of 0.141 mg/ml.
2. What is the concentration of this product? (lot YI052614DS)
   • The concentration of lot YI052614DS is 0.051 mg/ml.

Bioinformatics

• Gene Symbol: APOE
• Entrez:
  • 348(Human)
  • 11816(Mouse)
  • 25728(Rat)
• Uniprot:
  • P02649()